Abstract: Systems and methods according to one or more embodiments are provided for classifying and counting objects that pass through monitored zones in a field of view of an imaging device. An imaging device receives a series of images of a target scene having at least one monitored zone. An image processor extracts a target line of image values from each image, and adds the target line to a first spatio-temporal image. An edge detector and a cluster analysis module analyzes the first spatio-temporal image to identify objects associated with the at least one zone. An object classifier classifies in object and stores tracking information.

Abstract: Systems and methods according to one or more embodiments are provided for detecting an object in a field of view of an imaging device. An object may be detected by an imaging device when the object is present along a trajectory in a target scene. In one example, a system includes a memory component to store a plurality of images of the target scene and a processor. The processor is configured to define the trajectory between two locations within the target scene and extract a subset of pixel values from each of successive images corresponding to the trajectory. The extracted subsets of pixel values are processed to detect an object within the target scene. Additional systems and methods are also provided.

Abstract: An infrared (IR) imaging module may capture a background image in response to receiving IR radiation from a background of a scene and determine background calibration terms using the background image. The determined background calibration terms may be scale factors and/or offsets that equalize the pixel values of the background image to a baseline, value. IR imaging device may use the background calibration terms to capture images that have the baseline value for pixels corresponding to IR radiation received from the background and higher values (or lower values) for pixels corresponding to IR radiation received from a foreground. Such images may be used to count people and generate a heat map. The background calibration terms may be updated periodically, with the update period being increased at least for some pixels or a pixel area when a person is detected.

Abstract: The invention relates to a polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, wherein the polypeptide carries a half-life extending moiety and is administered in molar excess over Factor VIII and/or endogenous VWF.

Abstract: The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.

Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Abstract: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.

Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.

Abstract: The present invention relates to a covalent complex of von Willebrand Factor (VWF) and Factor VIII, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events.

Abstract: A system and method for comparing and searching for digital data, such as images, using histograms includes receiving a source image, receiving a comparison image, generating a first histogram for the source image and generating a second histogram for the comparison image. The source image may be received from a network device, such as a computer or camera, and the comparison image may one of a plurality of stored images in a database. The histograms may correspond to an image characteristic, including a color histogram corresponding to the distribution of the intensity of a corresponding color among image pixels in the source image. Each of first and second histograms is normalized and a similarity score is calculated between the two histograms. The similarity score represents a similarity measure between the two histograms, calculated from a subset of bins, which are independently selected for each image.

Abstract: The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.

Abstract: The invention relates to a compound, preferably an antibody, capable of binding to the receptor protein CLEC10A for use in the treatment of a blood coagulation disorder.

Abstract: The present invention relates to a covalent complex of von Willebrand Factor (VWF) and Factor VIII, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events.

Abstract: The invention relates among others to a protein comprising a fragment of 30-240 amino acids of Collagen and calcium-binding EGF domain-containing protein 1 (CCBE1) having 0-10 amino acid substitutions with respect to the amino acid sequence of SEQ ID NO: 1, wherein said fragment comprises at least a collagen domain of CCBE1, or a variant thereof comprising 1, 2 or 3 amino acid substitutions. The invention further describes means and methods for the treatment of individuals with the protein or protein binding thereto.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: Systems and methods according to one or more embodiments are provided for detecting an object in a field of view of an imaging device. An object may be detected by an imaging device when the object is present along a trajectory in a target scene. In one example, a system includes a memory component to store a plurality of images of the target scene and a processor. The processor is configured to define the trajectory between two locations within the target scene and extract a subset of pixel values from each of successive images corresponding to the trajectory. The extracted subsets of pixel values are processed to detect an object within the target scene. Additional systems and methods are also provided.

Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.

Abstract: The invention relates to a method for automatic flushing of fluid lines, in particular potable water lines. The invention further relates to a device for automatic flushing of fluid lines, in particular potable water lines. The invention is based on the technical problem to provide a method and a device for automatic flushing which allows a flushing behaviour that is better-suited to the circumstances and more reliable. The technical problem is solved by a method for automatic flushing of at least one fluid line, in particular a potable water line, in which a temperature profile of the fluid is measured, in which the measured data are evaluated and in which the automatic flushing of the at least one fluid line is influenced by an outcome of the evaluation.

Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.